Olema Pharmaceuticals, Inc. (OLMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.75+0.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OLMA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
OLMA — earnings miss
Dated 2026-08-10
as Exhibit 99.1 hereto and is incorporated herein by reference. The information in Item 2.02, including the press release attached as Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by…
Why it matters: This partnership is key for Olema's growth. Progress could boost investor confidence.
Supportive ifA press release about new updates or important steps in the partnership.
Worry ifNo news or bad updates about the partnership for a long time.
Why it matters: Positive results could validate OP-3136's potential as a treatment option. This would support Olema's growth strategy.
Supportive ifEarly results from the OP-3136 trial show strong anti-tumor effects.
Worry ifEarly results from the OP-3136 trial show weak anti-tumor effects.
Why it matters: This collaboration could enhance OP-3136's development and market potential. It is a new priority for Olema.
Supportive ifEarly results from the partnership show positive outcomes for OP-3136.
Worry ifThere are no updates or bad results from the Bayer collaboration.
Why it matters: This data will show if palazestrant is effective for breast cancer treatment. Positive results could boost Olema's growth prospects.
Supportive ifTop-line data from the OPERA-01 trial shows positive results in patients with ER+/HER2- breast cancer.
Worry ifData from OPERA-01 shows no clear benefits or bad results.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$209 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $644 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,435 loss on $10,000 · 74.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This partnership may help develop OP-3136. It could show promise for treating prostate cancer.
Supportive ifThere are early positive results from the OP-3136 and darolutamide trial.
Worry ifThere are no updates or bad results from the Bayer partnership.
Why it matters: Maintaining cash is crucial for funding operations and growth. A drop could signal trouble.
Worry ifQuarterly report shows cash position above $500M.
Less concerning ifCash position falls below $500M in the next quarterly report.
Why it matters: Progress in this study is crucial for validating OP-3136's potential as a cancer treatment.
Supportive ifEnrollment in the Phase 1 study of OP-3136 continues to meet or exceed expectations.
Worry ifEnrollment stalls or fails to meet expectations in the OP-3136 Phase 1 study.